Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling

17 Jan 2018

Abstract excerpt

OBJECTIVE: In patients with severe or refractory juvenile dermatomyositis (DM), second-line treatments may be required. Cyclophosphamide (CYC) is used to treat some connective tissue diseases, but evidence of its efficacy in juvenile DM is limited. This study was undertaken to describe clinical improvement in juvenile DM patients treated with CYC and model the efficacy of CYC treatment compared to no CYC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Inflammatory Myopathies and Dermatomyositis
Share to Rheumatoid Arthritis Research and Therapies
Share to Systemic Sclerosis and Related Diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29342499
DOI: 10.1002/art.40418

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural ModelingPMID 29342499Read ↗

Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians.Semantic proximity Read ↗

Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease.Semantic proximity Read ↗

Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisonsSemantic proximity Read ↗

Efficacy and safety of a triple combination of glucocorticoids, tofacitinib and calcineurin inhibitors in anti-MDA5 positive dermatomyositisSemantic proximity Read ↗

Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity IndexSemantic proximity Read ↗

Clinical Characteristics of New-onset Dermatomyositis with Adverse Outcomes: a retrospective cohort studySemantic proximity Read ↗

Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.Semantic proximity Read ↗

Yang’s Classification of Juvenile TMJ Anterior Disc Displacement Contributing to Treatment protocolsSemantic proximity Read ↗

Efficacy and safety of intraarticular corticosteroid injections in adolescents with juvenile idiopathic arthritis in the temporomandibular joint: A Norwegian 2-year prospective multicenter pilot study.Semantic proximity Read ↗

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic ArthritisSemantic proximity Read ↗

Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositisSemantic proximity Read ↗

Comparative effectiveness of natalizumab and fingolimod and injectable therapies in patients with pediatric multiple sclerosis: A registry-based retrospective cohort studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.